ABSTRACT
Tuberculous Meningitis (TBM) is the most severe form of TB with high mortality and morbidity. The treatment of TBM is not evidence-based, but is similar to the treatment of pulmonary TB. As a key drug in the treatment of TB, rifampicin—a concentration-dependent antibiotic—has a low penetration into the CSF. The current dose of rifampicin is very low and a higher dose of rifampicin might improve the treatment outcome. A series of studies have been conducted to determine whether a higher dose of rifampicin would give a better pharmacokinetic profile, be tolerated by patients, and improve the treatment outcome in TBM patients. This work is the result of collaborative research, funded by different research grants, both national and international.
